Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
8.49
-0.25 (-2.86%)
Nov 2, 2026, 4:00 PM EST - Market closed
Benitec Biopharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 179.97 | 97.74 | 50.87 | 2.48 | 4.06 |
Cash & Short-Term Investments | 179.97 | 97.74 | 50.87 | 2.48 | 4.06 |
Cash Growth | 84.13% | 92.16% | 1953.53% | -39.02% | -79.45% |
Accounts Receivable | - | - | - | 0.06 | 0 |
Other Receivables | 0 | 0.03 | 0.23 | - | - |
Receivables | 0 | 0.03 | 0.23 | 0.06 | 0 |
Prepaid Expenses | 1.6 | 0.63 | 0.52 | 1.18 | 0.74 |
Restricted Cash | 0.11 | 0.11 | 0.06 | 0.01 | 0.01 |
Total Current Assets | 181.69 | 98.52 | 51.67 | 3.73 | 4.82 |
Property, Plant & Equipment | 0.87 | 0.99 | 0.45 | 0.61 | 0.99 |
Other Long-Term Assets | 0.07 | 0.08 | 0.09 | 0.12 | 0.16 |
Total Assets | 182.62 | 99.59 | 52.21 | 4.46 | 5.97 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.91 | 0.2 | 1.35 | 1.14 | 0.42 |
Accrued Expenses | 0.66 | 0.52 | 0.65 | 0.74 | 0.7 |
Current Portion of Leases | 0.5 | 0.35 | 0.28 | 0.28 | 0.25 |
Other Current Liabilities | 3.27 | 0.72 | 2.64 | 1.82 | 1.16 |
Total Current Liabilities | 5.34 | 1.8 | 4.92 | 3.98 | 2.53 |
Long-Term Leases | 0.27 | 0.5 | - | 0.28 | 0.56 |
Pension & Post-Retirement Benefits | - | - | 0.04 | - | - |
Total Liabilities | 5.61 | 2.3 | 4.96 | 4.26 | 3.09 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0 | 0 | 0 | - | - |
Additional Paid-In Capital | 451.7 | 326.31 | 238.4 | 168.92 | 152.45 |
Retained Earnings | -273.72 | -228.18 | -190.26 | -167.89 | -148.33 |
Comprehensive Income & Other | -0.96 | -0.84 | -0.89 | -0.83 | -1.25 |
Shareholders' Equity | 177.01 | 97.3 | 47.25 | 0.2 | 2.88 |
Total Liabilities & Equity | 182.62 | 99.59 | 52.21 | 4.46 | 5.97 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.76 | 0.85 | 0.28 | 0.56 | 0.81 |
Net Cash (Debt) | 179.21 | 96.9 | 50.58 | 1.92 | 3.25 |
Net Cash Growth | 84.95% | 91.56% | 2537.23% | -41.00% | -83.38% |
Net Cash Per Share | 3.85 | 2.68 | 2.75 | 1.38 | 6.76 |
Filing Date Shares Outstanding | 34.88 | 26.25 | 10.56 | 2.55 | 0.48 |
Total Common Shares Outstanding | 34.42 | 26.25 | 10.09 | 1.65 | 0.48 |
Working Capital | 176.34 | 96.72 | 46.75 | -0.25 | 2.29 |
Book Value Per Share | 5.14 | 3.71 | 4.68 | 0.12 | 6.00 |
Tangible Book Value | 177.01 | 97.3 | 47.25 | 0.2 | 2.88 |
Tangible Book Value Per Share | 5.14 | 3.71 | 4.68 | 0.12 | 6.00 |
Machinery | 1.41 | 1.57 | 1.55 | 1.38 | 1.37 |
Leasehold Improvements | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |